Dr. Nikolai A. Podoltsev
Claim this profileYale University
Studies Acute Myeloid Leukemia
Studies Acute Lymphoblastic Leukemia
6 reported clinical trials
27 drugs studied
Area of expertise
1Acute Myeloid Leukemia
BCR-ABL1 positive
FLT3 positive
D835 positive
2Acute Lymphoblastic Leukemia
BCR-ABL1 positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Nikolai A. Podoltsev is currently running
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
Tuspetinib
for Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study.
Recruiting1 award Phase 1 & 222 criteria
More about Nikolai A. Podoltsev
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Nikolai A. Podoltsev has experience with
- Venetoclax
- Methotrexate
- Vincristine Sulfate
- Cytarabine
- Dexamethasone
- Cyclophosphamide
Breakdown of trials Nikolai A. Podoltsev has run
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Lymphoma
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nikolai A. Podoltsev specialize in?
Nikolai A. Podoltsev focuses on Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved BCR-ABL1 positive patients, or patients who are FLT3 positive.
Is Nikolai A. Podoltsev currently recruiting for clinical trials?
Yes, Nikolai A. Podoltsev is currently recruiting for 3 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Nikolai A. Podoltsev has studied deeply?
Yes, Nikolai A. Podoltsev has studied treatments such as Venetoclax, Methotrexate, Vincristine Sulfate.
What is the best way to schedule an appointment with Nikolai A. Podoltsev?
Apply for one of the trials that Nikolai A. Podoltsev is conducting.
What is the office address of Nikolai A. Podoltsev?
The office of Nikolai A. Podoltsev is located at: Yale University, New Haven, Connecticut 06520 United States. This is the address for their practice at the Yale University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.